By the Numbers: What it Costs to Operate a Biopharmaceutical Facility - Trend to smaller, less costly cities takes hold - BioPharm International

ADVERTISEMENT

By the Numbers: What it Costs to Operate a Biopharmaceutical Facility
Trend to smaller, less costly cities takes hold


BioPharm International


WHY GO TO SMALL CITIES?

A lower cost of living, especially the ability to buy more house for the money, is an additional advantage of the smaller cities. This is particularly the case when compared to the extremely high housing costs associated with tradi-tional biopharma industry hubs like Boston, San Francisco, New Jersey, and the Washington DC suburbs (Fairfax County, VA and Montgomery County, MD.) It is increasingly difficult for our clients to attract young, entry-level talent to these traditional locations, principally due to the prohibitively expensive housing markets there. States like South Dakota and Florida, which have no state personal income tax, provide additional relocation benefits to biotech transferees by enabling them to keep more of what they earn.

Increasingly, quantitative cost factors will trump other more quali-tative and subjective site selection variables within the boardrooms of major biopharma companies. Venture capital lenders, many burned by the dot-com crash, are asking small biopharmas and start-ups, "Do you really need to pay high rents or exorbitant relocation bonuses in costly markets like California's Bay Area, Boston's Route 128, or Washington, D.C.'s suburbs?

John H.Boyd is founder and president of The Boyd Company, Inc., 301 N.Harrison St. Suite 415, Princeton, NJ 08540, 609.890.0726, fax:609.588.0518,
http://www.theboydcompany.com/.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here